Keros Therapeutics’ KER-050 to treat anaemia in myelodysplastic syndrome (MDS) patients needs 30% of Phase II part 2 trial participants to become transfusion independent, a secondary endpoint, to be worth investigating further in Phase III, experts said.
Omeros’ (NASDAQ:OMER) narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathies (HSCT-TMA) will easily replace Alexion Pharmaceuticals’ (NASDAQ:ALXN) Soliris (eculizumab) as the current off-label standard of care (SOC) when approved, experts said.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped 7 points as of 12 April, according to GlobalData’s LoA data.
The likelihood of approval (LoA) of Outlook Therapeutics’ (NASDAQ:OTLK) Phase III Lytenava (bevacizumab-vikg) in diabetic macular edema (DME) rose 7 points, with its prospects in branch retinal vein occlusion (BRVO) jumping by 10 as of 6 April, according to GlobalData’s LoA data.
While Outlook Therapeutics’ Phase III neovascular age-related macular degeneration (AMD) trial for bevacizumab-vikg has experts expecting success, they were less optimistic about its market penetration.